RNA Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

Harga

$12.84

Kapitalisasi Pasar

$10.91B

P/E (TTM)

-14.5

EPS (TTM)

$-4.97

Pendapatan (TTM)

$19M

Imbal Hasil Dividen

—

ROE

-47.5%

D/E Utang/Ekuitas

—

Rentang 52M

$12 – $73

RNA Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

Pendapatan & Laba Bersih $19M

2018-12-31 → 2025-12-31

EPS $-4.97

2020-12-31 → 2025-12-31

Arus Kas Bebas $-664M

2020-12-31 → 2025-12-31

Margin -3650.4%

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Metrik

Tren 5 Tahun

RNA

Median Rekan

P/E (TTM)

-14.5

2.4

P/S (TTM)

581.5

15.2

P/B

6.5

1.4

Price / FCF (Harga / FCF)

-16.4

—

Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC

Metrik

Tren 5 Tahun

RNA

Median Rekan

Operating Margin (Margin Operasi)

-3977.3%

—

Net Profit Margin (Margin Laba Bersih)

-3650.4%

-946.2%

ROA

-38.9%

-52.8%

ROE

-47.5%

-60.2%

ROIC

-44.2%

—

Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca

Metrik

Tren 5 Tahun

RNA

Median Rekan

Current Ratio (Rasio Lancar)

9.2

7.4

Quick Ratio (Rasio Cepat)

2.0

—

Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T

Metrik

Tren 5 Tahun

RNA

Median Rekan

Revenue YoY (Pendapatan YoY)

72.1%

—

Revenue CAGR 3Y (CAGR Pendapatan 3T)

26.7%

—

Revenue CAGR 5Y (CAGR Pendapatan 5T)

22.5%

—

Metrik Per Saham EPS, nilai buku per saham, arus kas per saham, dividen per saham

Metrik

Tren 5 Tahun

RNA

Median Rekan

EPS (Diluted)

$-4.97

—

Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang

Metrik

Tren 5 Tahun

RNA

Median Rekan

RNA Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

BELI 5 analis

Beli Kuat 1 20,0%
Beli 3 60,0%
Tahan 1 20,0%
Jual 0 0,0%
Jual Kuat 0 0,0%

Target Harga 12 Bulan

2 analis · 2026-05-20

Rendah $25.00

Tinggi $25.00

Target median $25.00 +94,8%

Target rata-rata $25.00 +94,8%

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

Kejutan Rata-rata

0.09%

Periode	EPS Aktual	EPS Estimasi	Kejutan
31 Maret 2026	$-0.97	$-1.06	0.09%

Perbandingan Sejawat Metrik utama vs rekan sektor

Ticker	Kapitalisasi Pasar	P/E	Pendapatan YoY	Margin Bersih	ROE	Margin Kotor
RNA	$10.91B	-14.5	72.1%	-3650.4%	-47.5%	—
FHTX	$306M	-4.6	36.8%	-240.3%	80.2%	—
NERV	$174M	-0.1	—	—	339.5%	—
FATE	$113M	-0.9	-51.2%	-2051.1%	-58.2%	—
WHWK	$114M	-7.3	-72.5%	-288.3%	-13.4%	—
IKT	$270M	-4.2	111.0%	-1299.0%	-38.2%	—
KROS	$398M	8.9	—	35.7%	17.2%	—
BDTX	$139M	6.2	—	31.9%	18.3%	—
VYGR	$232M	-1.9	-49.5%	-296.5%	-54.4%	—
UNCY	$128M	-3.5	-29.0%	—	-113.9%	—

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

Laporan Laba Rugi 15

Data Laporan Laba Rugi Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2022	2021	2020	2019
Revenue	$19M	$11M	$10M	$9M	·	$9M	$7M	$2M
R&D Expense	$559M	$304M	$191M	$150M	·	$101M	$38M	$15M
SG&A Expense	$206M	$86M	$54M	$38M	·	$26M	$13M	$5M
Operating Expenses	$765M	$390M	$245M	$188M	·	$127M	$51M	$20M
Operating Income	$-746M	$-379M	$-236M	$-179M	·	$-118M	$-44M	$-17M
Interest Expense	·	·	·	$0	·	$0	$209.0K	$7M
Other Non-op	$-2M	$-248.0K	$-594.0K	$-57.0K	·	$-62.0K	$-75.0K	$0
Pretax Income	$-685M	$-322M	$-212M	·	·	·	·	·
Income Tax	$0	$0	$0	$0	·	$0	$0	$0
Net Income	$-685M	$-322M	$-212M	$-174M	·	$-118M	$-44M	$-25M
EPS (Basic)	$-4.97	$-2.89	$-2.91	$-3.34	·	$-2.85	$-2.05	·
EPS (Diluted)	$-4.97	$-2.89	$-2.91	$-3.34	·	$-2.85	$-2.05	·
Shares (Basic)	137,710,000	111,582,000	73,012,000	52,162,000	·	41,428,000	21,663,000	·
Shares (Diluted)	137,710,000	111,582,000	73,012,000	52,162,000	·	41,428,000	21,663,000	·
EBITDA	$-746M	$-379M	$-236M	$-179M	·	$-118M	$-44M	·

Neraca 24

Data Neraca Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2022	2021	2020	2019
Cash & Equivalents	$383M	$220M	$185M	$340M	·	$320M	$321M	$95M
Short-term Investments	·	·	·	·	·	$85M	$7M	·
Receivables	·	$0	$1M	$2M	·	·	·	·
Prepaid Expense	$102M	$41M	$16M	$12M	·	$6M	·	·
Other Current Assets	$53M	$19M	·	$2M	·	·	·	·
Current Assets	$1.80B	$1.54B	$611M	$623M	·	$411M	$332M	$96M
PP&E (Net)	$23M	$13M	$8M	$6M	·	$5M	$1M	$631.0K
PP&E (Gross)	$35M	$21M	$14M	$9M	·	$7M	$3M	$2M
Accum. Depreciation	$12M	$8M	$5M	$3M	·	$2M	$2M	$2M
Other Non-current Assets	$82M	$521.0K	$301.0K	$598.0K	·	$599.0K	$47.0K	$600.0K
Total Assets	$1.96B	$1.56B	$629M	$639M	·	$428M	$334M	$97M
Accounts Payable	$12M	$8M	$9M	$5M	·	$3M	$8M	$2M
Current Liabilities	$195M	$98M	$81M	$52M	·	$30M	$15M	$10M
Capital Leases	$45M	$3M	$6M	$8M	·	$10M	$938.0K	$393.0K
Other Non-current Liabilities	·	·	·	·	·	·	·	$45.0K
Total Liabilities	$269M	$139M	$128M	$61M	·	$46M	$28M	$28M
Long-term Debt	·	·	·	·	·	·	·	$5M
Common Stock	$15.0K	$12.0K	$8.0K	$7.0K	·	$5.0K	$4.0K	$0
Paid-in Capital	·	·	·	$939M	·	$566M	$373M	$-43M
Retained Earnings	$-1.58B	$-893M	$-571M	$-359M	·	$-185M	$-67M	$-22M
AOCI	$3M	$3M	$125.0K	$-3M	·	$-187.0K	$-5.0K	·
Stockholders' Equity	$1.69B	$1.42B	$501M	$578M	$374M	$381M	$306M	$-65M
Liabilities + Equity	$1.96B	$1.56B	$629M	$639M	·	$428M	$334M	$97M
Shares Outstanding	151,205,000	119,893,000	79,275,000	69,768,000	52,081,000	47,754,000	37,569,000	2,989,000

Arus Kas 10

Data Arus Kas Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2022	2021	2020	2019
Stock-based Comp	$98M	$51M	$38M	$27M	·	$17M	$4M	$406.0K
Operating Cash Flow	$-650M	$-301M	$-119M	$-136M	·	$-95M	$-37M	$2M
CapEx	$13M	$7M	$4M	$3M	·	$4M	$1M	$235.0K
Investing Cash Flow	$-38M	$-854M	$-130M	$-190M	·	$-83M	$-8M	$-235.0K
Net Debt Issued	·	·	·	$0	·	$0	$-5M	·
Stock Issued	$837M	$762M	$61M	$345M	$82M	$175M	$274M	·
Net Stock Activity	$837M	$762M	$61M	$345M	$82M	$20M	·	·
Financing Cash Flow	$851M	$1.19B	$94M	$346M	·	$176M	$272M	$89M
Net Change in Cash	$163M	$37M	$-155M	$20M	·	$-1M	$227M	$91M
Free Cash Flow	$-664M	$-308M	$-123M	$-139M	·	$-99M	$-38M	·

Profitabilitas 7

Data Profitabilitas Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2022	2021	2020	2019
Operating Margin	-3977.3%	-3477.4%	-2464.4%	-1939.6%	·	-1265.8%	-652.4%	·
Net Margin	-3650.4%	-2957.7%	-2219.9%	-1886.3%	·	-1265.4%	-653.5%	·
Pretax Margin	-3650.4%	·	·	·	·	·	·	·
EBITDA Margin	-3977.3%	-3477.4%	-2464.4%	-1939.6%	·	-1265.8%	-652.4%	·
ROA	-38.9%	-29.4%	-33.5%	-32.6%	·	-31.0%	-20.6%	·
ROE	-47.5%	-22.0%	-41.7%	-36.4%	·	-30.4%	-14.2%	·
ROIC	-44.2%	·	·	·	·	·	·	·

Likuiditas & Solvabilitas 3

Data Likuiditas & Solvabilitas Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2022	2021	2020	2019
Current Ratio	9.2	15.7	7.6	12.0	·	13.9	22.7	·
Quick Ratio	2.0	2.2	2.3	6.6	·	13.7	22.5	·
Interest Coverage	·	·	·	·	·	·	-211.9	·

Efisiensi 2

Data Efisiensi Tahunan untuk RNA
Metrik	Tren	2025	2024	2023	2022	2022	2021	2020	2019
Asset Turnover		0.0	0.0	0.0	0.0	·	0.0	0.0	·
Receivables Turnover		·	19.7	5.5	·	·	·	·	·

Per Saham 5

Data Per Saham Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2022	2021	2020	2019
Book Value / Share	$11.17	$11.89	$6.32	$8.29	·	$7.99	$8.15	·
Revenue / Share	$0.14	$0.10	$0.13	$0.18	·	·	·	·
Cash Flow / Share	$-4.72	$-2.70	$-1.63	$-2.61	·	·	·	·
Cash / Share	$2.53	$1.83	$2.33	$4.88	·	$6.71	$8.56	·
EPS (TTM)	$-4.97	$-2.89	$-2.91	$-3.34	$-3.01	$-2.85	$-2.05	·

Tingkat Pertumbuhan 3

Data Tingkat Pertumbuhan Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2022	2021	2020	2019
Revenue YoY	72.1%	14.0%	3.6%	-1.1%	·	37.4%	·	·
Revenue CAGR 3Y	26.7%	5.3%	12.1%	·	·	·	·	·
Revenue CAGR 5Y	22.5%	·	·	·	·	·	·	·

Valuasi (TTM) 10

Data Valuasi (TTM) Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2022	2021	2020	2019
Revenue TTM	$19M	$11M	$10M	$9M	$9M	$9M	$7M	·
Net Income TTM	$-685M	$-322M	$-212M	$-174M	$-136M	$-118M	$-44M	·
Market Cap	$10.91B	$3.49B	$717M	$1.55B	·	$1.14B	$959M	·
P/E	-14.5	-10.1	-3.1	-6.6	-4.8	-8.3	-12.4	·
P/S	581.5	319.9	75.0	167.8	·	121.7	141.3	·
P/B	6.5	2.4	1.4	2.7	·	3.0	3.1	·
P / Tangible Book	6.5	2.4	1.4	2.7	·	3.0	3.1	·
P / Cash Flow	-16.8	-11.6	-6.0	-11.4	·	-12.0	-25.8	·
P / FCF	-16.4	-11.3	-5.8	-11.1	·	-11.5	-25.1	·
Earnings Yield	-6.9%	-9.9%	-32.1%	-15.0%	-20.7%	-12.0%	-8.0%	·

Laporan Laba Rugi 12

Data Triwulanan Laporan Laba Rugi untuk RNA
Metrik	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue	$860.0K	$12M	$4M	$2M	$3M	$2M	$2M	$4M	$2M	$3M	$2M	$2M	$3M	$2M	$2M	$2M
R&D Expense	$167M	$155M	$138M	$99M	$96M	$77M	$64M	$67M	$53M	$48M	$43M	$48M	$46M	$37M	$40M	$28M
SG&A Expense	$89M	$46M	$37M	$34M	$28M	$23M	$21M	$14M	$16M	$14M	$12M	$12M	$10M	$10M	$9M	$9M
Operating Expenses	$255M	$201M	$175M	$133M	$124M	$100M	$85M	$81M	$69M	$61M	$55M	$60M	$56M	$47M	$48M	$36M
Operating Income	$-254M	$-189M	$-171M	$-132M	$-121M	$-98M	$-83M	$-77M	$-67M	$-59M	$-53M	$-58M	$-53M	$-45M	$-46M	$-34M
Other Non-op	$-477.0K	$-380.0K	$-651.0K	$-435.0K	$201.0K	$-232.0K	$-116.0K	$-101.0K	$-105.0K	$-13.0K	$-162.0K	$-314.0K	$-18.0K	$-12.0K	$-2.0K	$-25.0K
Net Income	$-237M	$-174M	$-157M	$-116M	$-102M	$-80M	$-71M	$-69M	$-60M	$-52M	$-47M	$-52M	$-50M	$-44M	$-46M	$-34M
EPS (Basic)	$-1.59	$-1.27	$-1.21	$-0.90	$-0.80	$-0.65	$-0.65	$-0.79	$-0.80	$-0.71	$-0.66	$-0.74	$-0.89	$-0.82	$-0.92	$-0.71
EPS (Diluted)	$-1.59	$-1.27	$-1.21	$-0.90	$-0.80	$-0.65	$-0.65	$-0.79	$-0.80	$-0.71	$-0.66	$-0.74	$-0.89	$-0.82	$-0.92	$-0.71
Shares (Basic)	-259,039,000	137,895,000	129,622,000	129,232,000	-205,933,000	123,375,000	106,928,000	87,212,000	-142,908,000	74,097,000	71,390,000	70,433,000	-99,080,000	53,069,000	49,927,000	48,246,000
Shares (Diluted)	-259,039,000	137,895,000	129,622,000	129,232,000	-205,933,000	123,375,000	106,928,000	87,212,000	-142,908,000	74,097,000	71,390,000	70,433,000	-99,080,000	53,069,000	49,927,000	48,246,000
EBITDA	·	$-189M	$-171M	$-132M	·	$-98M	$-83M	$-77M	·	$-59M	$-53M	$-58M	·	$-45M	·	$-34M

Neraca 21

Data Triwulanan Neraca untuk RNA
Metrik	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Cash & Equivalents	$383M	$350M	$244M	$254M	$220M	$370M	$576M	$471M	·	$86M	$154M	$119M	·	$144M	$125M	$139M
Short-term Investments	·	·	·	·	·	·	·	·	·	·	·	·	·	$262M	$273M	$258M
Receivables	·	·	·	·	·	$0	$0	$2M	·	·	$1M	·	·	·	·	·
Prepaid Expense	$102M	$90M	$67M	$55M	$41M	$33M	$30M	$19M	·	·	$11M	·	·	·	·	·
Other Current Assets	$53M	$60M	$43M	·	$19M	·	·	·	·	·	$6M	·	·	·	·	·
Current Assets	$1.80B	$1.97B	$1.25B	$1.43B	$1.54B	$1.62B	$1.33B	$934M	·	$555M	$595M	$597M	·	$414M	$404M	$405M
PP&E (Net)	$23M	$22M	$21M	$16M	$13M	$9M	$8M	$9M	·	$8M	$8M	$8M	·	$6M	$6M	$5M
PP&E (Gross)	$35M	$32M	$30M	$24M	$21M	$17M	$15M	$15M	·	$13M	$12M	$11M	·	$9M	$9M	$7M
Accum. Depreciation	$12M	$10M	$10M	$9M	$8M	$7M	$7M	$6M	·	$5M	$4M	$4M	·	$3M	$2M	$2M
Other Non-current Assets	$82M	$91M	$91M	$739.0K	$521.0K	$318.0K	$364.0K	$425.0K	·	$344.0K	$424.0K	$474.0K	·	$523.0K	$415.0K	$548.0K
Total Assets	$1.96B	$2.13B	$1.37B	$1.46B	$1.56B	$1.64B	$1.35B	$951M	·	$573M	$611M	$614M	·	$431M	$421M	$421M
Accounts Payable	$12M	$10M	$4M	$7M	$8M	$8M	$9M	$2M	·	$6M	$6M	$4M	·	$26M	$21M	$19M
Current Liabilities	$195M	$170M	$135M	$85M	$98M	$91M	$84M	$75M	·	$49M	$45M	$48M	·	$43M	$34M	$31M
Capital Leases	$45M	$46M	$1M	$2M	$3M	$4M	$5M	$5M	·	$7M	$6M	$7M	·	$8M	$9M	$9M
Total Liabilities	$269M	$248M	$176M	$130M	$139M	$137M	$126M	$121M	·	$56M	$52M	$55M	·	$54M	$46M	$45M
Common Stock	$15.0K	$15.0K	$12.0K	$12.0K	$12.0K	$12.0K	$11.0K	$10.0K	·	$7.0K	$7.0K	$7.0K	·	$5.0K	$5.0K	$5.0K
Retained Earnings	$-1.58B	$-1.34B	$-1.17B	$-1.01B	$-893M	$-791M	$-710M	$-640M	·	$-510M	$-458M	$-411M	·	$-308M	$-264M	$-219M
AOCI	$3M	$2M	$2M	$3M	$3M	$7M	$-453.0K	$-464.0K	·	$-2M	$-3M	$-2M	·	$-3M	$-3M	$-2M
Stockholders' Equity	$1.69B	$1.89B	$1.19B	$1.33B	$1.42B	$1.50B	$1.22B	$831M	$501M	$517M	$559M	$559M	$578M	$377M	$374M	$376M
Liabilities + Equity	$1.96B	$2.13B	$1.37B	$1.46B	$1.56B	$1.64B	$1.35B	$951M	·	$573M	$611M	$614M	·	$431M	$421M	$421M
Shares Outstanding	151,205,000	146,771,000	120,778,000	120,512,000	119,893,000	118,900,000	109,266,000	95,594,000	79,275,000	74,101,000	74,070,000	70,813,000	69,768,000	54,446,000	52,081,000	49,281,000

Arus Kas 9

Data Triwulanan Arus Kas untuk RNA
Metrik	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Stock-based Comp	$43M	$19M	$18M	$18M	$14M	$14M	$13M	$10M	$10M	$10M	$9M	$9M	$7M	$7M	$7M	$6M
Operating Cash Flow	$-170M	$-156M	$-200M	$-125M	$-100M	$-66M	$-65M	$-70M	$17M	$-37M	$-50M	$-49M	$-39M	$-32M	$-36M	$-30M
CapEx	$6M	$712.0K	$3M	$4M	$4M	$2M	$531.0K	$915.0K	$863.0K	$923.0K	$622.0K	$2M	$850.0K	$-107.0K	$1M	$758.0K
Investing Cash Flow	$207M	$-588M	$185M	$157M	$-64M	$-482M	$-275M	$-33M	$51M	$-31M	$46M	$-196M	$-8M	$11M	$-18M	$-175M
Stock Issued	$-538.0K	$837M	$0	$0	$-500.0K	$324M	$433M	$6M	$0	$0	$38M	$22M	$243M	$39M	$38M	$24M
Net Stock Activity	·	·	·	$0	·	·	·	$6M	·	·	·	$22M	·	·	·	$24M
Financing Cash Flow	$-5M	$850M	$4M	$2M	$14M	$342M	$447M	$389M	$32M	$40.0K	$39M	$23M	$244M	$40M	$39M	$24M
Net Change in Cash	$32M	$106M	$-10M	$34M	$-150M	$-206M	$107M	$286M	$99M	$-68M	$35M	$-222M	$197M	$19M	$-14M	$-181M
Free Cash Flow	·	·	·	$-129M	·	·	·	$-71M	·	·	·	$-51M	·	·	·	$-30M

Profitabilitas 5

Data Triwulanan Profitabilitas untuk RNA
Metrik	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Operating Margin	·	-1513.5%	-4448.7%	-8360.9%	·	-4200.9%	-4040.4%	-2178.6%	·	-2080.4%	-2272.6%	-2579.3%	·	-1810.2%	·	-1919.8%
Net Margin	·	-1398.3%	-4089.3%	-7360.0%	·	-3441.7%	-3461.8%	-1943.4%	·	-1858.0%	-2030.4%	-2346.3%	·	-1756.6%	·	-1907.2%
EBITDA Margin	·	-1513.5%	-4448.7%	-8360.9%	·	-4200.9%	-4040.4%	-2178.6%	·	-2080.4%	-2272.6%	-2579.3%	·	-1810.2%	·	-1919.8%
ROA	·	-9.2%	-11.6%	-9.6%	·	-7.3%	-7.2%	-8.8%	·	-10.4%	-9.1%	-10.1%	·	-10.2%	·	-9.3%
ROE	·	-10.3%	-13.0%	-10.7%	·	-8.0%	-8.0%	-9.9%	·	-11.7%	-10.1%	-11.2%	·	-11.3%	·	-10.3%

Likuiditas & Solvabilitas 2

Data Triwulanan Likuiditas & Solvabilitas untuk RNA
Metrik	Tren	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Current Ratio		·	11.6	9.3	16.9	·	17.8	15.8	12.5	·	11.4	13.1	12.4	·	9.7	·	13.1
Quick Ratio		·	2.1	1.8	3.0	·	4.1	6.8	6.3	·	1.8	3.4	2.5	·	9.5	·	12.8

Efisiensi 2

Data Triwulanan Efisiensi untuk RNA
Metrik	Tren	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Asset Turnover		·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	·	0.0
Receivables Turnover		·	·	·	·	·	·	3.5	4.5	·	·	3.9	·	·	·	·	·

Per Saham 5

Data Triwulanan Per Saham untuk RNA
Metrik	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Book Value / Share	·	$12.85	$9.87	$11.03	·	$12.64	$11.17	$8.69	·	$6.98	$7.55	$7.89	·	$6.92	·	$7.62
Revenue / Share	·	$0.09	$0.03	$0.01	·	$0.02	$0.02	$0.04	·	$0.04	$0.03	$0.03	·	$0.05	·	·
Cash Flow / Share	·	·	·	$-0.97	·	·	·	$-0.81	·	·	·	$-0.70	·	·	·	·
Cash / Share	·	$2.39	$2.02	$2.11	·	$3.11	$5.27	$4.93	·	$1.16	$2.08	$1.68	·	$2.64	·	$2.83
EPS (TTM)	·	$-4.03	$-3.41	$-2.99	·	$-2.80	$-2.81	$-2.90	·	$-2.93	$-3.14	$-3.19	·	$-3.13	·	·

Valuasi (TTM) 10

Data Triwulanan Valuasi (TTM) untuk RNA
Metrik	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue TTM	·	$20M	$10M	$9M	·	$11M	$11M	$11M	·	$10M	$9M	$9M	·	$9M	·	$9M
Net Income TTM	·	$-528M	$-424M	$-336M	·	$-272M	$-239M	$-221M	·	$-195M	$-189M	$-176M	·	$-153M	·	$-114M
Market Cap	·	$6.39B	$3.43B	$3.56B	·	$5.46B	$4.46B	$2.44B	·	$473M	$821M	$1.09B	·	$889M	·	$910M
P/E	·	-10.8	-8.3	-9.9	·	-16.4	-14.5	-8.8	·	-2.2	-3.5	-4.8	·	-5.2	·	·
P/S	·	316.1	350.0	374.6	·	508.4	416.3	223.6	·	48.0	89.2	125.1	·	103.2	·	98.2
P/B	·	3.4	2.9	2.7	·	3.6	3.7	2.9	·	0.9	1.5	1.9	·	2.4	·	2.4
P / Tangible Book	·	3.4	2.9	2.7	·	3.6	3.7	2.9	·	0.9	1.5	1.9	·	2.4	·	2.4
P / Cash Flow	·	·	·	-28.5	·	·	·	-34.7	·	·	·	-22.2	·	·	·	-30.8
P / FCF	·	·	·	-27.7	·	·	·	-34.2	·	·	·	-21.4	·	·	·	-30.0
Earnings Yield	·	-9.2%	-12.0%	-10.1%	·	-6.1%	-6.9%	-11.4%	·	-45.9%	-28.3%	-20.8%	·	-19.2%	·	·

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

Laporan Laba Rugi

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Pendapatan	$19M	$11M	$10M	$9M	$9M
Margin Operasi %	-3977.3%	-3477.4%	-2464.4%	-1939.6%	-1265.8%
Laba Bersih	$-685M	$-322M	$-212M	$-174M	$-118M
EPS Dilusian	$-4.97	$-2.89	$-2.91	$-3.34	$-2.85

Neraca

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Rasio Lancar	9.2	15.7	7.6	12.0	13.9
Rasio Cepat	2.0	2.2	2.3	6.6	13.7

Arus Kas

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Arus Kas Bebas	$-664M	$-308M	$-123M	$-139M	$-99M

Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini

CureVac menuntut Moderna atas pelanggaran paten vaksin COVID-19 Yahoo Finance · 3 minggu, 3 hari lalu

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

📊

Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.

Pilihan Anda disimpan dan mengikuti Anda di semua ticker.

RNA Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

RNA Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

Rata-rata bergerak dan lapisan tumpang tindih

Volume

Osilator

Momentum dan tren

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC

Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca

Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T

Metrik Per Saham EPS, nilai buku per saham, arus kas per saham, dividen per saham

Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang

RNA Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

Target Harga 12 Bulan

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

Perbandingan Sejawat Metrik utama vs rekan sektor

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap